Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
Blood Cancer Discovery (2023) Vol. 4, Iss. 4, pp. 276-293
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Wei‐Ying Jen, Hagop M. Kantarjian, Tapan M. Kadia, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 30-47
Open Access | Times Cited: 17
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Ayalew Tefferi, Hassan B. Alkhateeb, Naseema Gangat
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Michael Wysota, Marina Konopleva, Shane Mitchell
Current Oncology Reports (2024) Vol. 26, Iss. 4, pp. 409-420
Open Access | Times Cited: 12
Advancements and Challenges in the Treatment of AML
Yasmin Abaza, Christine M. McMahon, Jacqueline S. Garcia
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 12
New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches
Jaime L. Roman Diaz, Mariola Vazquez Martinez, Farhad Khimani
Cancers (2024) Vol. 16, Iss. 3, pp. 677-677
Open Access | Times Cited: 11
AML treatment: conventional chemotherapy and emerging novel agents
Mark Forsberg, Marina Konopleva
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 5, pp. 430-448
Closed Access | Times Cited: 11
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Harry Fruchtman, Zachary M. Avigan, Julian A. Waksal, et al.
Leukemia (2024) Vol. 38, Iss. 5, pp. 927-935
Open Access | Times Cited: 10
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet, Guillermo Garcia‐Manero, Nicholas J. Short, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 4, pp. e276-e286
Closed Access | Times Cited: 8
Venetoclax Resistance in Acute Myeloid Leukemia
Sylvain Garciaz, Marie‐Anne Hospital, Yves Collette, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1091-1091
Open Access | Times Cited: 8
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
An Overview of Targeted Therapies in Acute Myeloid Leukemia
Sven Turkalj, Felix A. Radtke, Paresh Vyas
HemaSphere (2023) Vol. 7, Iss. 6, pp. e914-e914
Open Access | Times Cited: 19
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
Boaz Nachmias, Shlomzion Aumann, Arnon Haran, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1146-1158
Open Access | Times Cited: 7
Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches
Karanpreet Singh Bhatia, Vedant Sandhu, Mei Hsuan Wong, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Gus O. Nwosu, David M. Ross, Jason A. Powell, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 6
Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study
Lei Zhao, Jinjun Yang, Mengran Chen, et al.
Annals of Hematology (2024) Vol. 103, Iss. 4, pp. 1197-1209
Closed Access | Times Cited: 5
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers
Yasmin Abaza, Eric S. Winer, Guru Subramanian Guru Murthy, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 606-614
Open Access | Times Cited: 5
Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Ximu Sun, Han Zhou, Yanming Li, et al.
Future Journal of Pharmaceutical Sciences (2025) Vol. 11, Iss. 1
Open Access
SOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions
Vishrut Shah, Farhad Ravandi
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations
Ludovic Gabellier, Enzo Bosetta, Maël Heiblig, et al.
Trends in cancer (2025)
Closed Access
Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents
Keith W. Pratz, Harry P. Erba
American Journal of Hematology (2025) Vol. 100, Iss. S2, pp. 16-22
Open Access
Selecting optimal therapy for higher-risk myelodysplastic syndromes: present and future projections
Farzad Teymouri, Constantin A Dasanu
Expert Opinion on Pharmacotherapy (2025)
Open Access
Will Triplet Therapy Become Standard of Care in Acute Myeloid Leukemia?
Yuchen Liu, Yasmin Abaza, Jessica K. Altman
Advances in Oncology (2025)
Closed Access
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Jayastu Senapati, Tapan M. Kadia, Naval Daver, et al.
Cancer (2025) Vol. 131, Iss. 7
Closed Access
Page 1 - Next Page

Scroll to top